













1382HLA-Allele Matched Unrelated Donors Compared
to HLA-Matched Sibling Donors: Role of Cell Source
and Disease Risk Category
Ann Woolfrey,1,2 Stephanie J. Lee,1,3 Ted A. Gooley,1 Mari Malkki,1
Paul J. Martin,1,3 John M. Pagel,1,3 John A. Hansen,1,3 Effie Petersdorf1,3To determine whether the risks of allogeneic transplantation are different when the donor is a fully matched
unrelated donor (MUD; based on 10/10 HLA alleles) compared to an HLA-identical sibling, we performed
a retrospective analysis of 1448 patients with high-risk or advanced hematologic malignancies given T-replete
grafts after myeloablative conditioning. No statistically significant differences were found between recipients
of a matched sibling donor (MSD) and 10/10 MUD in survival, disease-free survival (DFS), and nonrelapse
mortality (NRM) for patients with high-risk disease or those given bone marrow as a graft source. However,
for patients with intermediate-risk disease receiving peripheral blood grafts, we observed higher NRM and
lower overall survival (OS) in the 10/10MUD group compared to theMSD cohort. Graft-versus-host disease
(GVHD) was higher in the MUD group compared to the MSD group. These results suggest that if a patient
has high-risk disease and an MSD is not available, selection of an HLA-allele-matched MUDmay provide sim-
ilar OS and DFS, and therefore lack of an MSD in and of itself should not preclude such a patient from un-
dergoing transplantation. However, for patients with intermediate-risk disease, transplantation with
peripheral blood from a 10/10 MUD is associated with lower survival than an MSD.
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donorINTRODUCTION
Outcomes after unrelated donor hematopoietic cell
transplantation (HCT) for treatment of hematologic
malignancies are improved by matching human leuko-
cyte antigen (HLA) alleles of the donor and recipient
[1,2]. These studies further indicate that the risks
associated with HLA-mismatching depend upon the
type and stage of disease at the time of HCT, the iden-
tity of the mismatched locus, and the total number of
mismatches. Although matching for HLA-A, -B, -C,
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6/j.bbmt.2010.03.024outcome of unrelated HCT, it is not clear whether
this level of matching can be viewed as equivalent to
aHLA-matched siblingdonor (MSD). In aprospective,
genetically randomized trial conducted by the French
Society of Bone Marrow Transplantation and Cell
Therapy (SFGM-TC), disease-free survival (DFS)
among 55 recipients with an unrelated donor matched
for 8/8 plus DQB1 alleles (10/10MUD) was not statis-
tically different from results among 181 recipients with
MSD [3]. A recent retrospective study from the Center
for International Bone Marrow Transplant Research
found that DFS was lower for adult patients with
acute myelogenous leukemia (AML) who received 8/
8 MUD (n 5 340) compared to MSD grafts
(n5 1271), but not for those with acute lymphoblastic
leukemia (ALL, n 5 672) or chronic myelogenous
leukemia (CML, n 5 1816) [4]. Both studies include
a large proportion of patients with chronic phase
CML forwhomHCT is no longer considered frontline
therapy. For that reason, we compared transplant
outcomes in a large number of patients with higher
risk hematologic malignancies given 10/10 MUD or
MSD, all treated during the same time period and given
similar supportive care at a single transplant center.
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Patient Population
The study cohort included 1448 consecutive
patients who received HCT with a 10/10 MUD
(n 5 563) or MSD (n 5 885) HCT at the Fred
Hutchinson Cancer Research Center for treatment
of a hematologic malignancy between March 1992
and February 2008. All patients were prepared with
a myeloablative conditioning regimen with standard
supportive care as previously described [1]. All pa-
tients gave informed consent for the transplant and
for the use of medical information for research.
This retrospective study was approved by the institu-
tional review board of the Fred Hutchinson Cancer
Research Center (FHCRC).
Histocompatibility testing for donor selection was
performed by theClinical Immunogenetics Laboratory
at FHCRC for all patients and donors using previously
described methods [5-7]. For unrelated transplants
before 2002, HLA-A, -B, and -C alleles of the donor
and recipient were typed retrospectively by
DNA-sequencing methods as previously described [1].
For subsequent unrelated transplants, HLA-A, -B, -C,
-DRB1, and -DQB1 alleles were typed prospectively
by oligonucleotide hybridization or by DNA sequenc-
ingmethods [1].Compatibility of thedonorwith the re-
cipient was tested further by lymphocyte crossmatch
(patient serum versus donor T and B cells) before
HCT [8].Disease Risk
The pretransplant risk category was defined as
intermediate or high, according to the diagnosis and
disease stage at the time of HCT, as previously
described [2]. High-risk diseases included advanced
acute leukemias (refractory disease or beyond second
remission [.CR2]), advanced myelodysplastic syn-
drome (MDS) (refractory anemia with excess blasts
[RAEB] or RAEB in transformation [RAEBT]),
CML in blast crisis, or high-grade lymphoma beyond
first remission (.CR1). Intermediate-risk diseases in-
cluded acute leukemias in CR2, CML in accelerated
phase or second chronic phase, early-phase MDS (re-
fractory anemia [RA] or refractory anemia with ring
sideroblasts [RARS]), myelofibrosis (MF), or other
myeloproliferative disorders. In addition, we defined
patients with acute leukemia in CR1 as intermediate
risk, provided at least 1 of the following poor-risk
features was present: high-risk cytogenetics, more
than 1 course of chemotherapy required to attain
CR1 (poor responders), leukemia evolving from
MDS or after treatment of a previous malignancy (sec-
ondary leukemia), or CR1 marrow with early extrame-
dullary relapse [9]. With the exception of these CR1
patients with poor-risk features, early-stage disease[2] was not included in the analysis because HCT plays
a limited role in current therapy [10].Statistical Methods
Time-to-event endpoints included overall mor-
tality, DFS (where failure is the earliest of death or
relapse), nonrelapse mortality (NRM) (death without
a prior relapse), relapse, and clinical extensive
chronic graft-versus-host disease (cGVHD). Grades
II-IV and III-IV acute GVHD (aGVHD) were
treated as binary outcomes. Overall survival (OS)
and DFS were estimated by the method of Kaplan
and Meier [11]. Probabilities of NRM, relapse, and
cGVHD were summarized as cumulative incidence
estimates. Cox regression was used to assess the asso-
ciation of donor source with the hazard of failure for
time-to-event endpoints, with censoring of follow-up
at the date of last contact among patients with no fail-
ure event. Logistic regression was used to examine
the association of donor source with the probability
of aGVHD. Performance scores were treated as
a continuous variable for comparison by linear re-
gression between groups. Scores were also dichoto-
mized as 90-100 versus below 90 for comparison by
logistic regression between groups. All models were
adjusted for disease risk as defined before, patient
age at the time of transplant, prior cytomegalovirus
(CMV) infection of the donor and recipient, patient
and donor sex (male patient with female donor versus
all others), type of graft (bone marrow (BM) versus
mobilized peripheral blood [PBSC]), use of total
body irradiation (TBI) in the conditioning regimen,
GVHD prophylaxis (methotrexate/cyclosporine
(MTX/CsA) versus others), and year of HCT (mod-
eled as a continuous linear variable), regardless of the
statistical significance of each with outcome or the
distribution of each factor in the 2 donor groups. Po-
tential interactions were tested by including appro-
priate terms in the regression models. All 2-sided
P-values from regression models were derived from
the Wald test, and no adjustments were made for
multiple comparisons.RESULTS
Comparison of Study Groups
Patient characteristics at transplantation are sum-
marized in Table 1. The proportion of patients with
high-risk disease was lower in the 10/10 MUD group,
but other characteristics appeared not to be greatly im-
balanced between the 2 groups. The statistical models
were adjusted for the variables in Table 1, as well as for
year of HCT, regardless of the statistical significance
or the distribution of each factor in the 2 donor groups.
Table 1. Characteristics of Patients Transplanted fromEither
Siblings or Unrelated Donors Matched for HLA-A, -B, -C,
-DRB1, and -DQB1 Alleles
Matched Sibling 10/10 Unrelated
Total number patients 885 563
Diagnosis
Acute leukemia 526 (59%) 317 (56%)
CR1 171 122
CR2 105 101
>CR2 or relapse 250 94
Chronic myelogenous leukemia 78 (9%) 79 (14%)
Accelerated phase 42 53
Blast crisis 23 12
Chronic phase $2 13 14
Myelodysplastic syndrome 193 (22%) 109 (19%)
RA/RARS 78 50
RAEB/RAEBT 115 59
Myelofibrosis 54 (6%) 29 (5%)
Myeloproliferative syndromes 27 (3%) 27 (5%)
Other 7 (1%) 2 (<1%)
Risk group
Intermediate 491 (55%) 398 (71%)
High 394 (45%) 165 (29%)
Median age in years (range) 43.6 (0.6-69.3) 40.8 (0.6-67.0)
Patient/donor CMV
Patient + 489 (55%) 289 (51%)
2/+ 112 (13%) 66 (12%)
2/2 252 (28%) 202 (36%)
Unknown 32 (4%) 6 (1%)
TBI-based conditioning regimen 472 (53%) 320 (57%)
Stem cell source
Bone marrow 416 (47%) 265 (47%)
PBSC 469 (53%) 298 (53%)
Sex match
Female into female 189 (21%) 97 (17%)
Female into male 227 (26%) 114 (20%)
Male into female 164 (19%) 149 (26%)
Male into male 305 (34%) 203 (36%)
CMV indicates cytomegalovirus; CR, complete remission; HLA, human
leukocyte antigen; RA/RARS, refractory anemia/refractory anemia
with ringed sideroblasts; RAEB/RAEBT, RA with excess blasts/RA with
excess blasts in transformation; PBSC, peripheral blood stem cells;
TBI, total body irradiation.
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As of October 2008, 319 (57%) of the patients in
the 10/10 MUD group and 543 (61%) in the MSD
group had died. Median follow-up among survivors
was 5.1 years (range: 0.5-16.3 years) in the MUD
group and 6.3 years (range: 0.1-16.4 years) in the
MSD group. The adjusted hazard of mortality tended
to be higher in the 10/10MUDgroup compared to the
MSD group, although the difference was not statisti-
cally significant and the magnitude of the difference
was small (hazard ratio [HR] 5 1.12, 95% confidence
interval [CI] 0.96-1.31, P 5 .14). There was no statis-
tical interaction between donor relationship and recip-
ient age (P5 .82, age as a continuous linear variable) or
pretransplant disease risk category (intermediate ver-
sus high risk, P 5 .59). However, when the product
(BM or PBSC) was considered, the association be-
tween donor relationship and mortality showed a de-
pendence on product type and severity of disease(P 5 .005, three-way interaction test). In other words,
the effect of the donor relationship depended upon
whether BM or PBSC was used, and the effect within
a particular type of cell product depended upon the
pretransplant risk category. Specifically, there was no
difference inmortality between the 10/10MUDgroup
compared to the MSD group for recipients of BM (re-
gardless of disease severity) or high-risk PBSC recipi-
ents. Intermediate-risk patients who received PBSC
from a 10/10 MUD, however, had a higher risk of
mortality compared to intermediate-risk patients
who received PBSC from an MSD (Table 2). There
was a trend toward higher risk for mortality when all
intermediate-risk patients who received 10/10 MUD
(BM or PBSC) were compared only to those given
PBSC from anMSD (HR 1.26, CI 0.98-1.60, P5 .07).
Among patients in the 10/10 MUD group, 333
(59%) either died or had recurrent malignancy com-
pared to 582 (66%) in the MSD group. The adjusted
hazard of mortality or relapse showed no statistically
significant difference between the 2 groups (HR 5
1.05, CI 0.90-1.22, P 5 .56). The association between
donor relationship and DFS showed no suggestion of
a dependence on recipient age (P5 .74), nor was there
an association with disease risk (P 5 .48), unless the
type of graft was considered. Again, we found evidence
of a 3-way interaction between donor relationship,
type of graft, and severity of disease (P 5 .01). Specif-
ically, for intermediate-risk recipients, the risk of fail-
ure with PB grafts was higher with 10/10 MUD than
with MSD (Table 2). Accordingly, intermediate-risk
patients who have a 10/10 MUD PBSC donor incur
a modest increase in risk of treatment failure compared
to those with an MSD (Figure 1). No difference
between the 10/10 MUD and MSD groups was
observed for high-risk recipients of PBSC or for
recipients of BM regardless of disease severity.NRM and Recurrent Malignancy
In the 10/10 MUD group, 184 (33%) of the
patients died without prior recurrent malignancy,
compared to 277 (31%) in the MSD group. The ad-
justed hazard of NRM was statistically significantly
higher in the 10/10 MUD group than in the MSD
group, but there was a suggestion of the same 3-way
interaction seen in both OS and DFS (P 5 .10). For
consistency with the results for OS and DFS, the
results are presented for all 4 donor types and donor
source groups. The risk of NRM was higher among
intermediate-risk unrelated PBSC recipients com-
pared to the relevant MSD recipients (Table 2). The
association did not depend on recipient age (P 5 .89).
Recurrent malignancy occurred in 149 (26%) of
the patients in the 10/10 MUD group and in 305
(34%) of those in the MSD group. The adjusted
hazard of relapse was suggestively lower among all
Table 2. Adjusted Hazard Ratios for Overall Mortality, Relapse/Death (Failure for Disease-Free Survival), Nonrelapse Mortality,
and Relapse According to Source of Stem Cells and Severity of Disease
Hazard Ratio 95% CI P-value Interaction P-value*
Overall mortality
BM, Intermediate 0.81 0.59-1.12 .20
BM, High 1.07 0.76-1.50 .71 .005
PBSC, intermediate 1.62 1.21-2.17 .001
PBSC, high 0.94 0.66-1.35 .75
Mortality or relapse
BM, intermediate 0.79 0.58-1.07 .12
BM, high 1.00 0.71-1.40 .99 .01
PBSC, intermediate 1.44 1.09-1.90 .01
PBSC, high 0.84 0.59-1.18 .30
Nonrelapse mortality
BM, intermediate 1.06 0.70-1.61 .79
BM, high 1.52 0.96-2.42 .07 .10
PBSC, intermediate 1.87 1.26-2.78 .002
PBSC, high 1.05 0.64-1.74 .84
Relapse
BM, intermediate 0.59 0.37-0.93 .02
BM, high 0.63 0.38-1.04 .07 .17
PBSC, intermediate 1.08 0.73-1.61 .69
PBSC, high 0.67 0.41-1.07 .09
BM indicate bone marrow; CI, confidence interval; MUD, matched unrelated donor; PBSC, peripheral blood stem cells.
Hazard ratios represent the hazard of failure in the 10/10 MUD group relative to the hazard of failure in the matched-sibling donor group.
*Interaction P-value from likelihood ratio test comparing model without interaction terms to model with 3-way interaction terms.
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the MSD group (HR 5 0.79, 95% CI 0.64-0.98,
P5 .04). The 3-way interaction for relapse was some-
what suggestive (P5 .17), although not as strong as for
OS and NRM or DFS.
aGVHD and cGVHD
Among patients who were graded, grades II-IV
aGVHD occurred in 450 of 550 (82%) patients in
the 10/10 MUD group compared to 577 of 827
(70%) patients in the MSD group (Table 3). After ad-
justing for the factors described before, the odds of
grades II-IV GVHD were higher in the 10/10 MUD
group compared to the MSD group (odds ratio
[OR]5 1.77, 95%CI 1.33-2.36, P5 .0001). The sameFigure 1. Disease-free survival (DFS) according to cell source. Kaplan-Mier es
ripheral blood stemcell (PBSC) grafts (right panel) are stratified for disease-risk c
[MSD] or aHLA-matched unrelated donor [10/10MUD]). Among BMgraft recip
10/10 MUD grafts; similarly for high-risk disease, 177 received MSD and 82 rece
risk disease, 252 received MSD and 215 received 10/10 MUD grafts; similarly foqualitative conclusions applied for grades III-IV
aGVHD, which developed in 123 (22%) of the pa-
tients in the 10/10 MUD group and in 160 (19%) of
those in the MSD group, leading to an adjusted
OR5 1.50 (95%CI 1.11-2.04, P5 .009). These associa-
tions did not depend on age and showed minimal
dependence on source of stem cells and severity of
disease (3-way interaction, P 5 .40 for grades II-IV,
P 5 .86 for grades III-IV).
Clinical extensive cGVHD occurred in 253 (45%)
of the patients in the 10/10 MUD group compared to
370 (42%) of those in theMSDgroup, leading to an ad-
justedHR5 1.34 (95%CI 1.12-1.60, P5 .001). There
was no evidence to suggest a dependence of this associ-
ation on source of stem cells and disease risk (3-waytimates of DFS among recipients of bone marrow (BM, left panel) or pe-
ategory (intermediate versus high) and donor type (HLA-matched sibling
ientswith intermediate-risk disease, 239 receivedMSDand 183 received
ived 10/10 MUD grafts. Among PBSC graft recipients with intermediate-
r high-risk disease, 217 received MSD and 83 received 10/10 MUD grafts.
Table 3. Acute Graft-versus-Host Disease in Recipients of
HLA-Matched Sibling Donor or 10/10 Allele-Matched
Unrelated Donor Hematopoietic Cell Transplants
Grade* Matched Sibling 10/10 MUD
0 203 (25%) 87 (16%)
I 47 (6%) 13 (2%)
II 417 (50%) 327 (59%)
III 136 (16%) 94 (17%)
IV 24 (3%) 29 (5%)
HLA indicates human leukocyte antigen; MSD, matched sibling donor;
MUD, matched unrelated donor.
*Grade was unknown in 28 (3%) MSD and 9 (2%) MUD patients.
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in the 10/10 MUD group, we found no difference in
performance scores at time of last contact. Specifically,
the average Karnofsky/Lansky score in the 10/10
MUD group was 89.9 compared to 90.2 in the MSD
group (P 5 .76 adjusted for length of follow-up).DISCUSSION
The use of high-resolution HLA-typing has
allowed us to select an unrelated donor matched for
10/10HLA-alleles for a subset of our patients. Previous
studies from our center and the National Marrow
Donor Program (NMDP) have shown that recipient-
donor matching for at least 8/8 HLA alleles has
improved outcome of unrelated donor HCT. The
question then arises as to whether these very
well-matched unrelated donors should be considered
equivalent to the ‘‘gold standard’’ of HLA-matched
sibling donors. We addressed this question in a large
population of patients otherwise receiving identical
supportive care, and only included diagnoses that
generally are considered suitable for HCT from an
MSD, and excluded patients with chronic phase
CML or with acute leukemia in first remission, unless
high-risk features were present.
Overall, our results indicate that compared to the
entire cohort of MSD recipients, recipients of 10/10
MUD grafts have higher aGVHD and cGVHD, but
differ in OS, DFS, and NRM only when patients
have intermediate stage disease and PBSCs are used
as the graft source. If patients have high-risk disease,
or if BM is used, then theOS, DFS, andNRMbetween
10/10 MUD and MSD are not statistically signifi-
cantly different. Specifically, recommending alloge-
neic HCT for patients with intermediate risk
diseases, such as early phase MDS or acute leukemia
in CR1 or CR2, must take into consideration that
a 10/10 MUD PBSC graft may sustain a modest in-
crease in the risk of mortality after HCT.
Statistical models in this study were adjusted for
a number of factors, including the type of graft. Al-
though our results show a 3-way interaction between
donor relationship, severity of disease, and type ofgraft, the study was not designed to determine
whether the source of cells within a particular donor
group (MSD or 10/10 MUD) was associated with
a difference in survival. The question of whether 1
cell source is superior to another has been addressed
in prospective randomized trials. Compared to BM,
PBSC grafts from MSD have been associated with
improved OS, particularly among patients with
more advanced hematologic malignancies [12,13]. A
multicenter prospective randomized trial, sponsored
by the Clinical Trials Network, has recently
completed accrual, and the results may directly
answer the question for recipients of unrelated
donor grafts.
Two large studies from the NMDP showed that
survival after unrelated donor HCT was not affected
by donor-recipient HLA-DQB1 mismatch [2,14].
Accordingly, the NMDP consensus statement has
indicated that the optimal unrelated donor will be
matched for HLA-A, -B, -C, and -DRB1 alleles (8/8
match) [15]. Our data set did not include a sufficient
number of patient-donor pairs with an isolated
DQB1 mismatch to address this question, because
we have given preference to unrelated donors with an
HLA-class I mismatch over a class II mismatch when
a fully matched donor could not be identified.We cau-
tion that the conclusions from comparing results with
10/10 MUD and MSD in the current study might not
apply when comparing 8/8 MUD with MSD, particu-
larly if the prevalence of unrecognized HLA-DQB1
mismatching is high.
Results of this study expand the findings of 2
smaller studies reported previously. The prospective
study from SFGM-TC showed no statistically signifi-
cant difference between MUD and MSD in survival
after HCT, but the outcome analyses were adjusted
for the occurrence of GVHD, which may have
obscured any difference in survival related to the
increased risk of GVHD with MUD. Moreover, the
relatively small sample sizes (181 MSD, 55 MUD)
limited the power to observe a statistically significant
difference in this study [3]. The Essen group retro-
spectively compared HCT results for 101 patients
who were given 10/10 MUD, 86 patients given
HLA-mismatched related, and 138 patients given
MSD grafts and similarly found no statistically signif-
icant association of donor type with survival [16]. As
with the SFGM-TC study, however, the power in
the Essen study was limited by the sample size. Not
surprisingly, these studies as well as the current analy-
sis, show higher risks of aGVHD and cGVHD among
recipients of MUD grafts. Nonetheless, we find that
the MUD recipients have similar performance scores.
The large number of patients in the current analysis
thus establish more firmly the relative outcomes after
HCT with 10/10 MUD compared to MSD, and
particularly highlight the need to consider the
Biol Blood Marrow Transplant 16:1382-1387, 2010 1387Allele-Matched Unrelated HCTcell source and disease risk when making treatment
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